Process Chromatography: Five Decades of Innovation - - BioPharm International


Process Chromatography: Five Decades of Innovation

BioPharm International
Volume 20, Issue 10

Enter Membrane Chromatography

Figure 4. Comparison of diffusion in conventional bead resins and membrane adsorbers. In conventional beads, most of the binding sites are within the pores and pore diffusion is the major process by which target molecules bind to their ligands. In membrane adsorbers and perfusion chromatography beads, the pores are large enough for target molecules to reach their ligands by way of convection currents, with very little pre-diffusion necessary.51
Chromatography is generally understood to be a unit operation performed on a porous, beaded resin derivatized with appropriate binding ligands which confer the properties of ion exchange, HIC, affinity etc. Most separations are performed on beaded agarose and agarose–polymer matrices because the agarose does not generally interfere with the separation. The vast majority of potential binding sites are found in the pores, and one of the disadvantages of traditional packed-bed chromatography is that the separative process relies on pore diffusion to bring solute molecules into contact with their binding sites (Figure 4).

Such diffusion-dependence results in long process times at higher resin volumes.56 To a certain extent, the diffusion problem can be addressed by using smaller beads, which have a lower surface area to volume ratio. However, this introduces the further issues of pressure drop and bead compaction in the column, particularly at high flow rates. The pressure drop can be severe in long columns significantly reducing process efficiency.

In the 1970s, efforts were made to overcome the flow limitations posed by non-rigid resins by using the short, wide columns discussed by Janson.24 Twenty years later, the concept of "perfusion" chromatography was introduced with the benefits of highly porous particles with 8,000–10,000 "through-pores" giving linear flow rates of up to 1000 cm/h and more. Monolithic structures have also been developed in the 1990s in pursuit of resolution of the same problem.

The idea of membrane chromatography was born from the idea of combining the convective flow—low pressure advantage of membranes with their mass transfer capacity and led initially to the stacked membrane solutions. Membrane adsorbers are thin, synthetic microporous or macroporous membranes, which are chemically activated to fulfill the same function as chromatography resins. The development of the first membrane adsorbers by Brandt and colleagues in 198857 and other pioneers58–62 can be viewed as the equivalent of shortening the column to near zero length, allowing large-scale processes to run with only a small drop in pressure even at high flow rates, and therefore resulting in higher productivity. Additionally, because the transport of solutes to their binding sites occurs mainly by convection (while pore diffusion is minimal), the mass transfer resistance is reduced, so that capture is rapid and largely independent of flow rate (Figure 4). This allows very high flow rates to be used, reducing the overall process time by up to 100-fold. The most significant improvements have been seen with large molecules, which are often unable to migrate into the pores of traditional media and tend to bind only to ligands displayed on the bead surface.

Figure 5. Scanning electron micrograph showing ion exchange chromatography beads on the surface of a Sartobind Q membrane. 500-fold magnification.
The difference between bead and membrane-based chromatographic processing solutions is shown in Figure 5. It shows a scanning electron micrograph showing typical ion exchange chromatography resin on the surface of a derivatized membrane.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here